Colorectal cancer: Using blood samples and tumor tissue to detect K-ras mutations

Expert Review of Anticancer Therapy

Volumn 15, Issue 6, 2015, Pages 715-725

  Li, Yang ^a,b   Fu, Xiao Hong ^c   Yuan, Jin Qiu ^c   Yang, Zu Yao ^c   Mao, Chen ^c   Dong, Xiao Mei ^a   Tang, Jin Ling ^c   Wang, Sheng Yong ^a  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

blood; colorectal cancer; diagnostic test; K ras; meta analysis; mutation; plasma; serum

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BLOOD SAMPLING; CANCER TISSUE; CHAIN REACTION AMPLIFICATION REFRACTORY MUTATION SYSTEM; CO AMPLIFICATION AT LOWER DENATURATION TEMPERATURE POLYMERASE CHAIN REACTION; COLORECTAL CANCER; DENATURING GRADIENT GEL ELECTROPHORESIS; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; ETHNICITY; FALSE POSITIVE RESULT; GENE AMPLIFICATION; GENE MUTATION; GENETIC PROCEDURES; HUMAN; MUTANT ALLELE SPECIFIC AMPLIFICATION POLYMERASE CHAIN REACTION; ONCOGENE K RAS; PEPTIDE NUCLEIC ACID POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION ALLELE SPECIFIC AMPLIFICATION; PREDICTIVE VALUE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TAQMAN MUTATION DETECTION ASSAY; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; GENETICS; META ANALYSIS; MUTATION; ONCOGENE RAS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 84930448896     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1037836     Document Type: Article

References (66)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61: 69-90
2. Mohan S, Heitzer E, Ulz P, et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet 2014;10:e1004271
3. Lynch H, Lynch P, Lanspa S, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009;76:1-18
4. Soulières D, Greer W, Magliocco AM, et al. KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Curr Oncol 2010;17:S31-40
5. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25: 1658-64
6. Yen L-C, Uen Y-H, Wu D-C, et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg 2010;251:254-60
7. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-15
8. Pinto P, Rocha P, Veiga I, et al. Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. Cancer Genet 2011;204:439-46
9. Qiu L-X, Mao C, Zhang J, et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies. Eur J Cancer 2010;46:2781-7
10. Wang S, An T, Wang J, et al. Potential clinical significance of a plasma-based kras mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16:1324-30
11. Rogosnitzky M, Danks R. Validation of blood testing for K-ras mutations in colorectal and pancreatic cancer. Anticancer Res 2010;30:2943-7
12. Lefebure B, Charbonnier F, Fiore FD, et al. Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer. Ann Surg 2010;251:275-80
13. Ryan BM, Lefort F, McManus R, et al. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up. Gut 2003;52:101-8
14. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005;102: 16368-73
15. Boni L, Cassinotti E, Canziani M, et al. Free circulating DNA as possible tumour marker in colorectal cancer. Surg Oncol 2007;16:29-31
16. Di Fiore F, Charbonnier F, Lefebure B, et al. Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer. Br J Cancer 2008;99:551-2
17. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2007;14:985-90
18. Spindler KLG, Pallisgaard N, Vogelius I, et al. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 2012;18: 1177-85
19. Taly V, Pekin D, Benhaim L, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 2013;5912:1722-31
20. Morgan SR, Whiteley J, Donald E, et al. Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples. Clinical medicine insights. Pathology 2012;5:15-22
21. Pu X, Pan Z, Huang Y, et al. Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications. Oncol Lett 2013;5:249-54
22. Gutie-rrez C, Rodriguez J, Patinõ-Garcá A, et al. KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients. Oncol Lett 2013;6:1343-5
23. Thierry AR, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014;20: 430-5
24. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36
25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7: 177-88
27. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-29
28. Soeken KL, Sripusanapan A. Assessing publication bias in meta-analysis. Nurs Res 2003;52:57-60
29. Anker P, Lefort F, Vasioukhin V, et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 1997;112:1114-20
30. Lilleberg SL, Durocher J, Sanders C, et al. High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform. Ann N Y Acad Sci 2004;1022:250-6
31. Lindforss U, Zetterquist H, Papadogiannakis N, et al. Persistence of K-ras mutations in plasma after colorectal tumor resection. Anticancer Res 2005;25: 657-61
32. Yen LC, Yeh YS, Chen CW, et al. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 2009;15:4508-13
33. Yang MJ, Chiu HH, Wang HM, et al. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. Ann Surg Oncol 2010;17:624-33
34. Liu P, Liang H, Xue L, et al. Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan((R))-MGB probe genotyping method. Exp Ther Med 2012;4:109-12
35. Miyano S, Hanazawa K, Kitabatake T, et al. Detecting KRAS mutations in peripheral blood of colorectal cancer patients by peptide nucleic acid clamp PCR. Exp Ther Med 2012;4:790-4
36. Aung KL, Mullamitha S, Valle JW, et al. Non-invasive detection and monitoring of plasma KRAS mutation status in advanced colorectal cancer using Therascreen (R) KRAS RGQ PCR. Eur J Cancer 2013;49: S566-6
37. Janku F, Angenendt P, Naing A, et al. Actionable mutations in cell-free DNA in plasma of patients with advanced cancers referred for experimental targeted therapies. Mol Cancer Ther 2013;12:B26
38. Spindler KG, Appelt AL, Pallisgaard N, et al. KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer. Br J Cancer 2013;109:3067-72
39. Yamada T, Matsumoto S, Hayato K, et al. Liquid biopsy detecting KRAS mutations may be useful for prognostic or predictive marker. Colorectal Dis 2013;15:104-5
40. Kuo YB, Chen JS, Fand CW, et al. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin Chim Acta 2014;433c:284-9
41. Sefrioui D, Vasseur N, Sesboue R, et al. Plasma cell-free DNA and fraction of circulating KRAS mutations as prognostic in patients with metastatic colorectal cancer. J Clin Oncol 2014;32:B490
42. Spindler KL, Pallisgaard N, Andersen RF, et al. Changes in mutational status during third-line treatment for metastatic colorectal cancer-Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer 2014;135:2215-22
43. De Kok JB, Van Solinge WW, Ruers TJM, et al. Detection of tumour DNA in serum of colorectal cancer patients. Scand J Clin Lab Invest 1997;57:601-4
44. Iinuma H, Okinaga K, Adachi M, et al. Detection of tumor cells in blood using CD45 magnetic cell separation followed by nested mutant allele-specific amplification of p53 and K-ras genes in patients with colorectal cancer. Int J Cancer 2000;89: 337-44
45. Ryan BM, McManus RO, Daly JS, et al. Serum mutant K-ras in the colorectal adenoma-to-carcinoma sequence. Implications for diagnosis, postoperative follow-up, and early detection of recurrent disease. Ann N Y Acad Sci 2000;906:29-30
46. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62
47. Lievre A, Bachet J-B, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5
48. Hurwitz HI, Yi J, Ince W, et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009;14:22-8
49. Samowitz WS, Curtin K, Schaffer D, et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000;9:1193-7
50. Etienne-Grimaldi M-C, Formento J-L, Francoual M, et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008;14:4830-5
51. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-6.
52. Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
53. Han C-B, Li F, Ma J-T, et al. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest 2012;30:741-7
54. Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008;26: 4217-19
55. Baldus SE, Schaefer K-L, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-9
56. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-72
57. Thijssen M, Swinkels DW, Ruers T, et al. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res 2001;22: 421-5
58. Lee TH, Montalvo L, Chrebtow V, et al. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 2001;41:276-82
59. Jung M, Klotzek S, Lewandowski M, et al. Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem 2003;49:1028-9
60. Dieterle CP, Conzelmann M, Linnemann U, et al. Detection of isolated tumor cells by polymerase chain reaction-restriction fragment length polymorphism for K-ras mutations in tissue samples of 199 colorectal cancer patients. Clin Cancer Res 2004;10: 641-50
61. Otori K, Oda Y, Sugiyama K, et al. High frequency of K-ras mutations in human colorectal hyperplastic polyps. Gut 1997;40: 660-3
62. Däbritz J, Hänfler J, Preston R, et al. Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. Br J Cancer 2005;92:405-12
63. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28: 4697-705
64. Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25:1346-55
65. Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl 3):iii1-9
66. EMA. Available from: www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion/human/000558/WC500155463.pdf [Last accessed 10 November 2014]